Boone Capital Management LLC Makes New Investment in uniQure N.V. $QURE

Boone Capital Management LLC bought a new stake in uniQure N.V. (NASDAQ:QURE) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 147,317 shares of the biotechnology company’s stock, valued at approximately $8,599,000. uniQure comprises 2.8% of Boone Capital Management LLC’s holdings, making the stock its 14th biggest holding. Boone Capital Management LLC owned approximately 0.24% of uniQure as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of QURE. Private Trust Co. NA acquired a new stake in shares of uniQure in the 3rd quarter worth about $28,000. Jones Financial Companies Lllp boosted its stake in uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 509 shares during the period. Tower Research Capital LLC TRC grew its position in uniQure by 358.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,085 shares of the biotechnology company’s stock worth $99,000 after purchasing an additional 5,538 shares during the last quarter. Knott David M Jr bought a new position in uniQure in the 3rd quarter worth about $117,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of uniQure in the second quarter valued at approximately $215,000. Institutional investors own 78.83% of the company’s stock.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $15.53 on Friday. The stock has a market cap of $971.09 million, a price-to-earnings ratio of -4.50 and a beta of 0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43. uniQure N.V. has a 12 month low of $7.76 and a 12 month high of $71.50. The stock’s 50 day moving average price is $21.37 and its 200 day moving average price is $29.59.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. uniQure had a negative return on equity of 174.03% and a negative net margin of 1,236.00%.The firm had revenue of $5.57 million during the quarter, compared to analyst estimates of $4.84 million. Equities research analysts anticipate that uniQure N.V. will post -3.75 earnings per share for the current fiscal year.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and maintained a $70 price target on QURE, giving some institutional-support context despite lowered estimates. HC Wainwright Reaffirms “Buy” Rating for uniQure (NASDAQ:QURE)
• Neutral Sentiment: Market/opinion coverage is running — e.g., a Seeking Alpha piece frames uniQure’s situation as complex and worth reading for background, but it does not add new regulatory facts. A Unique Situation For UniQure
• Negative Sentiment: FDA reportedly issued an unprecedented public rebuke alleging uniQure pushed “distorted” or “manipulated” data related to AMT‑130; plaintiffs’ firms are citing that as the basis to expand securities investigations — a major regulatory risk for the company’s lead program and valuation. QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data …
• Negative Sentiment: Multiple law firms have filed or are soliciting plaintiffs in securities class actions (class period: Sept. 24–Oct. 31, 2025) and have set an April 13, 2026 lead‑plaintiff filing deadline — increasing legal and settlement-tail risk. Representative filings/alerts include Kessler Topaz, Pomerantz and Schall. uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz … QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit …
• Negative Sentiment: HC Wainwright materially cut near‑ and long‑term EPS forecasts (Q1–Q4 2026 and FY2026–FY2030), reducing future earnings visibility and implying a slower timeline to commercialization/profitability despite the Buy rating. That revision increases downside risk to current valuation. uniQure (NASDAQ: QURE) analyst/estimate coverage — MarketBeat

Insiders Place Their Bets

In other uniQure news, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares of the company’s stock, valued at approximately $557,575.92. This represents a 23.82% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jeannette Potts sold 3,412 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider owned 138,483 shares of the company’s stock, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 81,399 shares of company stock valued at $1,527,645. 4.79% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on QURE. Sanford C. Bernstein cut uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Royal Bank Of Canada upgraded uniQure from a “sector perform” rating to an “outperform” rating and raised their target price for the company from $11.00 to $35.00 in a research report on Monday, March 9th. Stifel Nicolaus set a $14.00 target price on uniQure in a research note on Monday, March 2nd. TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $9.00 price target (down from $55.00) on shares of uniQure in a report on Monday, March 2nd. Ten investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.25.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.